Share Price and Basic Stock Data
Last Updated: December 9, 2025, 1:49 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Dolphin Medical Services Ltd operates within the hospitals and medical services sector, a field characterized by its potential for steady growth driven by rising healthcare demands. The company’s revenue trajectory has shown some volatility, with sales recorded at ₹0.61 Cr for the fiscal year ending March 2023, a slight increase from ₹0.52 Cr the previous year. However, a closer look reveals a fluctuating quarterly performance, as evidenced by a dip in revenue to ₹0.08 Cr in March 2023, before rebounding to ₹0.18 Cr in September 2023. This inconsistency raises questions about the sustainability of its revenue streams. The company’s operating profit margin (OPM) stood at a modest 17.65%, suggesting that while there is some operational efficiency, it may not be sufficient to translate into consistent profitability, which is a crucial factor for long-term investors.
Profitability and Efficiency Metrics
The profitability indicators for Dolphin Medical Services present a mixed picture. While the OPM appears relatively stable, the company has struggled to achieve a positive net profit, reporting a net loss of ₹0.01 Cr for the fiscal year ending March 2023. This trend has persisted over the years, with net profits remaining elusive, as highlighted by consistent losses over the past decade. The return on equity (ROE) is currently at a mere 0.30%, indicating that shareholder investments are not yielding satisfactory returns. The company’s cash conversion cycle (CCC) of 30.42 days shows that it is managing its receivables and payables reasonably well, but the overall efficiency remains hampered by its inability to convert sales into profits effectively. Investors should note that ongoing operational challenges may hinder Dolphin Medical’s ability to improve profitability in the near future.
Balance Sheet Strength and Financial Ratios
On the balance sheet front, Dolphin Medical Services exhibits a cautious approach with borrowings recorded at ₹0.83 Cr, which is manageable relative to its market capitalization of ₹3.75 Cr. However, the company’s reserves are negative at ₹5.02 Cr, indicating a lack of retained earnings to cushion against future uncertainties. The price-to-book value ratio stands at a low 0.13x, suggesting that the stock may be undervalued, but it can also signify a lack of investor confidence in the company’s growth prospects. The interest coverage ratio (ICR) of 5.76x implies that the company is comfortably able to cover its interest obligations, which is a positive sign amid its ongoing operational losses. Overall, while the balance sheet appears to be in a reasonable state, the negative reserves raise concerns about Dolphin Medical’s long-term financial health.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Dolphin Medical Services indicates a significant public ownership at 73.57%, which reflects a broad base of retail investors. Promoters hold a stable 26.44%, suggesting that there is some level of commitment from the management. However, the lack of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) may signal a lack of institutional confidence in the company’s future. The number of shareholders has seen a slight increase to 9,349, which could indicate growing interest among retail investors, yet the overall public sentiment seems cautious given the company’s financial struggles. The absence of dividends further emphasizes the need for the company to focus on reinvesting profits to stabilize its operations and improve shareholder returns.
Outlook, Risks, and Final Insight
Looking ahead, Dolphin Medical Services faces a complex landscape. The healthcare sector holds promise, but the company’s persistent losses pose significant risks. Investors might consider the volatility in revenue and profitability metrics as red flags. Furthermore, the negative reserve situation could limit the company’s capacity to invest in growth initiatives. On the upside, if Dolphin can stabilize its operations and gradually transition towards profitability, it could unlock value for shareholders. However, the reliance on public ownership without institutional backing may lead to volatility in stock performance. Investors should weigh these risks against the potential for recovery in a growing sector, remaining cautious about the ongoing operational challenges that could impede progress.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Dolphin Medical Services Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 43.2 Cr. | 129 | 195/120 | 8.81 | 117 | 2.72 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 21.5 Cr. | 20.5 | 35.5/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 9.42 Cr. | 9.11 | 20.8/9.10 | 105 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 113 Cr. | 60.5 | 98.7/55.2 | 25.0 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 21.0 Cr. | 3.88 | 7.29/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 26,143.71 Cr | 753.34 | 93.41 | 99.39 | 0.34% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.15 | 0.16 | 0.22 | 0.08 | 0.15 | 0.18 | 0.20 | 0.14 | 0.14 | 0.25 | 0.24 | 0.14 | 0.17 |
| Expenses | 0.17 | 0.17 | 0.20 | 0.16 | 0.13 | 0.17 | 0.20 | 0.27 | 0.13 | 0.23 | 0.23 | 0.19 | 0.14 |
| Operating Profit | -0.02 | -0.01 | 0.02 | -0.08 | 0.02 | 0.01 | 0.00 | -0.13 | 0.01 | 0.02 | 0.01 | -0.05 | 0.03 |
| OPM % | -13.33% | -6.25% | 9.09% | -100.00% | 13.33% | 5.56% | 0.00% | -92.86% | 7.14% | 8.00% | 4.17% | -35.71% | 17.65% |
| Other Income | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | 0.01 |
| Profit before tax | -0.03 | -0.02 | 0.01 | -0.09 | 0.02 | 0.01 | 0.00 | -0.13 | 0.01 | 0.02 | 0.01 | -0.07 | 0.03 |
| Tax % | 0.00% | 0.00% | 0.00% | 11.11% | 0.00% | 0.00% | 7.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Net Profit | -0.03 | -0.01 | 0.01 | -0.10 | 0.01 | 0.01 | 0.00 | -0.13 | 0.01 | 0.02 | 0.01 | -0.07 | 0.03 |
| EPS in Rs | -0.02 | -0.01 | 0.01 | -0.07 | 0.01 | 0.01 | 0.00 | -0.09 | 0.01 | 0.01 | 0.01 | -0.05 | 0.02 |
Last Updated: August 19, 2025, 7:55 pm
Below is a detailed analysis of the quarterly data for Dolphin Medical Services Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.17 Cr.. The value appears strong and on an upward trend. It has increased from 0.14 Cr. (Mar 2025) to 0.17 Cr., marking an increase of 0.03 Cr..
- For Expenses, as of Jun 2025, the value is 0.14 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.19 Cr. (Mar 2025) to 0.14 Cr., marking a decrease of 0.05 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.03 Cr.. The value appears strong and on an upward trend. It has increased from -0.05 Cr. (Mar 2025) to 0.03 Cr., marking an increase of 0.08 Cr..
- For OPM %, as of Jun 2025, the value is 17.65%. The value appears strong and on an upward trend. It has increased from -35.71% (Mar 2025) to 17.65%, marking an increase of 53.36%.
- For Other Income, as of Jun 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.01 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.03 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.02 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.03 Cr.. The value appears strong and on an upward trend. It has increased from -0.07 Cr. (Mar 2025) to 0.03 Cr., marking an increase of 0.10 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is 0.03 Cr.. The value appears strong and on an upward trend. It has increased from -0.07 Cr. (Mar 2025) to 0.03 Cr., marking an increase of 0.10 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.02. The value appears strong and on an upward trend. It has increased from -0.05 (Mar 2025) to 0.02, marking an increase of 0.07.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:29 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.96 | 0.36 | 0.57 | 0.35 | 0.15 | 0.06 | 0.18 | 0.47 | 0.52 | 0.61 | 0.68 | 0.78 | 0.80 |
| Expenses | 1.06 | 0.39 | 0.39 | 0.33 | 0.23 | 0.20 | 0.52 | 6.24 | 0.66 | 0.69 | 0.76 | 0.78 | 0.79 |
| Operating Profit | -0.10 | -0.03 | 0.18 | 0.02 | -0.08 | -0.14 | -0.34 | -5.77 | -0.14 | -0.08 | -0.08 | 0.00 | 0.01 |
| OPM % | -10.42% | -8.33% | 31.58% | 5.71% | -53.33% | -233.33% | -188.89% | -1,227.66% | -26.92% | -13.11% | -11.76% | 0.00% | 1.25% |
| Other Income | 0.00 | 0.01 | 0.15 | 0.02 | 0.09 | -0.63 | 0.05 | 5.55 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Interest | 0.05 | 0.05 | 0.06 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
| Depreciation | 0.71 | 0.52 | 0.34 | 0.33 | 0.33 | 0.24 | 0.06 | 0.06 | 0.06 | 0.06 | 0.05 | 0.06 | 0.06 |
| Profit before tax | -0.86 | -0.59 | -0.07 | -0.30 | -0.33 | -1.02 | -0.36 | -0.29 | -0.17 | -0.11 | -0.10 | -0.03 | -0.01 |
| Tax % | 0.00% | -3.39% | -28.57% | -10.00% | -12.12% | -1.96% | 5.56% | 6.90% | 5.88% | 9.09% | 10.00% | 0.00% | |
| Net Profit | -0.86 | -0.57 | -0.05 | -0.27 | -0.30 | -1.01 | -0.39 | -0.31 | -0.19 | -0.12 | -0.10 | -0.03 | -0.01 |
| EPS in Rs | -0.57 | -0.38 | -0.03 | -0.18 | -0.20 | -0.67 | -0.26 | -0.21 | -0.13 | -0.08 | -0.07 | -0.02 | -0.01 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 33.72% | 91.23% | -440.00% | -11.11% | -236.67% | 61.39% | 20.51% | 38.71% | 36.84% | 16.67% | 70.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 57.51% | -531.23% | 428.89% | -225.56% | 298.05% | -40.87% | 18.20% | -1.87% | -20.18% | 53.33% |
Dolphin Medical Services Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 34% |
| 3 Years: | 14% |
| TTM: | 21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 14% |
| 3 Years: | 23% |
| TTM: | 91% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 11% |
| 3 Years: | 6% |
| 1 Year: | 0% |
| Return on Equity | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -1% |
| 3 Years: | -1% |
| Last Year: | 0% |
Last Updated: September 5, 2025, 3:16 pm
Balance Sheet
Last Updated: December 4, 2025, 2:46 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 | 15.10 |
| Reserves | -1.72 | -2.30 | -2.34 | -2.61 | -2.91 | -3.91 | -4.30 | -4.61 | -4.80 | -4.92 | -5.03 | -5.06 | -5.02 |
| Borrowings | 8.10 | 8.05 | 8.16 | 8.21 | 8.21 | 6.22 | 6.37 | 0.61 | 0.68 | 0.76 | 0.80 | 0.87 | 0.83 |
| Other Liabilities | 0.75 | 0.74 | 0.67 | 0.65 | 0.61 | 0.58 | 0.71 | 1.23 | 1.26 | 1.23 | 1.27 | 1.17 | 1.30 |
| Total Liabilities | 22.23 | 21.59 | 21.59 | 21.35 | 21.01 | 17.99 | 17.88 | 12.33 | 12.24 | 12.17 | 12.14 | 12.08 | 12.21 |
| Fixed Assets | 11.23 | 14.50 | 10.36 | 10.03 | 9.70 | 6.79 | 6.74 | 3.00 | 2.94 | 2.87 | 2.83 | 2.76 | 6.67 |
| CWIP | 5.93 | 2.14 | 5.93 | 5.93 | 5.93 | 5.93 | 5.93 | 4.09 | 4.09 | 4.09 | 4.09 | 4.09 | 0.31 |
| Investments | 0.52 | 0.52 | 0.52 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 | 0.41 |
| Other Assets | 4.55 | 4.43 | 4.78 | 4.98 | 4.97 | 4.86 | 4.80 | 4.83 | 4.80 | 4.80 | 4.81 | 4.82 | 4.82 |
| Total Assets | 22.23 | 21.59 | 21.59 | 21.35 | 21.01 | 17.99 | 17.88 | 12.33 | 12.24 | 12.17 | 12.14 | 12.08 | 12.21 |
Below is a detailed analysis of the balance sheet data for Dolphin Medical Services Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 15.10 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 15.10 Cr..
- For Reserves, as of Sep 2025, the value is -5.02 Cr.. The value appears to be improving (becoming less negative). It has improved from -5.06 Cr. (Mar 2025) to -5.02 Cr., marking an improvement of 0.04 Cr..
- For Borrowings, as of Sep 2025, the value is 0.83 Cr.. The value appears to be improving (decreasing). However, Reserves are negative, which is a major warning sign. It has decreased from 0.87 Cr. (Mar 2025) to 0.83 Cr., marking a decrease of 0.04 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1.30 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.17 Cr. (Mar 2025) to 1.30 Cr., marking an increase of 0.13 Cr..
- For Total Liabilities, as of Sep 2025, the value is 12.21 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 12.08 Cr. (Mar 2025) to 12.21 Cr., marking an increase of 0.13 Cr..
- For Fixed Assets, as of Sep 2025, the value is 6.67 Cr.. The value appears strong and on an upward trend. It has increased from 2.76 Cr. (Mar 2025) to 6.67 Cr., marking an increase of 3.91 Cr..
- For CWIP, as of Sep 2025, the value is 0.31 Cr.. The value appears to be declining and may need further review. It has decreased from 4.09 Cr. (Mar 2025) to 0.31 Cr., marking a decrease of 3.78 Cr..
- For Investments, as of Sep 2025, the value is 0.41 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.41 Cr..
- For Other Assets, as of Sep 2025, the value is 4.82 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.82 Cr..
- For Total Assets, as of Sep 2025, the value is 12.21 Cr.. The value appears strong and on an upward trend. It has increased from 12.08 Cr. (Mar 2025) to 12.21 Cr., marking an increase of 0.13 Cr..
However, the Borrowings (0.83 Cr.) are higher than the Reserves (-5.02 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -8.20 | -8.08 | -7.98 | -8.19 | -8.29 | -6.36 | -6.71 | -6.38 | -0.82 | -0.84 | -0.88 | -0.87 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Days | 36.50 | 36.50 | 21.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 33.18 | 30.42 |
| Days Payable | 12.17 | 73.00 | 0.00 | 0.00 | 0.00 | |||||||
| Cash Conversion Cycle | 24.33 | -36.50 | 21.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 33.18 | 30.42 |
| Working Capital Days | 589.32 | 1,449.86 | 1,171.84 | 2,106.57 | 4,891.00 | 11,619.17 | 3,629.72 | 986.28 | 898.46 | 771.89 | 687.06 | 645.77 |
| ROCE % | -3.69% | -2.55% | -0.05% | -0.96% | -1.56% | -1.69% | -2.02% | -1.98% | -1.45% | -0.91% | -0.83% | -0.18% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 16 | Mar 15 | Mar 14 | Mar 13 | Mar 12 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -0.03 | -0.38 | -0.57 | -1.31 | -0.99 |
| Diluted EPS (Rs.) | -0.03 | -0.38 | -0.57 | -1.31 | -0.99 |
| Cash EPS (Rs.) | 0.19 | -0.03 | -0.09 | -0.88 | -0.55 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 8.50 | 8.53 | 8.91 | 9.47 | 10.78 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 8.50 | 8.53 | 8.91 | 9.47 | 10.78 |
| Revenue From Operations / Share (Rs.) | 0.37 | 0.24 | 0.63 | 0.75 | 2.49 |
| PBDIT / Share (Rs.) | 0.21 | -0.02 | -0.06 | -0.39 | 0.25 |
| PBIT / Share (Rs.) | -0.01 | -0.36 | -0.53 | -0.82 | -0.17 |
| PBT / Share (Rs.) | -0.04 | -0.39 | -0.57 | -1.29 | -0.95 |
| Net Profit / Share (Rs.) | -0.03 | -0.38 | -0.57 | -1.31 | -0.98 |
| NP After MI And SOA / Share (Rs.) | -0.03 | -0.38 | -0.57 | -1.31 | -0.98 |
| PBDIT Margin (%) | 56.85 | -9.66 | -10.55 | -52.32 | 10.07 |
| PBIT Margin (%) | -2.35 | -146.84 | -85.02 | -108.98 | -7.09 |
| PBT Margin (%) | -12.23 | -156.99 | -89.80 | -170.48 | -38.47 |
| Net Profit Margin (%) | -8.16 | -152.48 | -90.22 | -173.28 | -39.61 |
| NP After MI And SOA Margin (%) | -8.16 | -152.48 | -90.22 | -173.28 | -39.61 |
| Return on Networth / Equity (%) | -0.36 | -4.48 | -6.46 | -13.88 | -9.18 |
| Return on Capital Employeed (%) | -0.06 | -2.56 | -3.67 | -5.36 | -1.08 |
| Return On Assets (%) | -0.21 | -2.65 | -3.87 | -8.49 | -6.03 |
| Long Term Debt / Equity (X) | 0.63 | 0.62 | 0.60 | 0.57 | 0.47 |
| Total Debt / Equity (X) | 0.63 | 0.62 | 0.60 | 0.57 | 0.47 |
| Asset Turnover Ratio (%) | 0.02 | 0.01 | 0.04 | 0.04 | 0.14 |
| Current Ratio (X) | 29.59 | 15.97 | 17.40 | 17.36 | 17.80 |
| Quick Ratio (X) | 29.46 | 15.89 | 17.10 | 17.01 | 17.49 |
| Interest Coverage Ratio (X) | 5.76 | -0.95 | -2.21 | -0.85 | 0.32 |
| Interest Coverage Ratio (Post Tax) (X) | 0.17 | -14.03 | -17.86 | -1.82 | -0.26 |
| Enterprise Value (Cr.) | 10.00 | 10.11 | 9.76 | 9.95 | 10.69 |
| EV / Net Operating Revenue (X) | 17.63 | 26.84 | 10.18 | 8.72 | 2.84 |
| EV / EBITDA (X) | 31.01 | -277.52 | -96.45 | -16.66 | 28.21 |
| MarketCap / Net Operating Revenue (X) | 3.12 | 5.29 | 1.67 | 1.46 | 0.78 |
| Price / BV (X) | 0.13 | 0.15 | 0.11 | 0.11 | 0.18 |
| Price / Net Operating Revenue (X) | 3.12 | 5.30 | 1.67 | 1.46 | 0.78 |
| EarningsYield | -0.02 | -0.28 | -0.53 | -1.19 | -0.50 |
After reviewing the key financial ratios for Dolphin Medical Services Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 16, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 15) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 16, the value is -0.03. This value is below the healthy minimum of 5. It has increased from -0.38 (Mar 15) to -0.03, marking an increase of 0.35.
- For Diluted EPS (Rs.), as of Mar 16, the value is -0.03. This value is below the healthy minimum of 5. It has increased from -0.38 (Mar 15) to -0.03, marking an increase of 0.35.
- For Cash EPS (Rs.), as of Mar 16, the value is 0.19. This value is below the healthy minimum of 3. It has increased from -0.03 (Mar 15) to 0.19, marking an increase of 0.22.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 16, the value is 8.50. It has decreased from 8.53 (Mar 15) to 8.50, marking a decrease of 0.03.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 16, the value is 8.50. It has decreased from 8.53 (Mar 15) to 8.50, marking a decrease of 0.03.
- For Revenue From Operations / Share (Rs.), as of Mar 16, the value is 0.37. It has increased from 0.24 (Mar 15) to 0.37, marking an increase of 0.13.
- For PBDIT / Share (Rs.), as of Mar 16, the value is 0.21. This value is below the healthy minimum of 2. It has increased from -0.02 (Mar 15) to 0.21, marking an increase of 0.23.
- For PBIT / Share (Rs.), as of Mar 16, the value is -0.01. This value is below the healthy minimum of 0. It has increased from -0.36 (Mar 15) to -0.01, marking an increase of 0.35.
- For PBT / Share (Rs.), as of Mar 16, the value is -0.04. This value is below the healthy minimum of 0. It has increased from -0.39 (Mar 15) to -0.04, marking an increase of 0.35.
- For Net Profit / Share (Rs.), as of Mar 16, the value is -0.03. This value is below the healthy minimum of 2. It has increased from -0.38 (Mar 15) to -0.03, marking an increase of 0.35.
- For NP After MI And SOA / Share (Rs.), as of Mar 16, the value is -0.03. This value is below the healthy minimum of 2. It has increased from -0.38 (Mar 15) to -0.03, marking an increase of 0.35.
- For PBDIT Margin (%), as of Mar 16, the value is 56.85. This value is within the healthy range. It has increased from -9.66 (Mar 15) to 56.85, marking an increase of 66.51.
- For PBIT Margin (%), as of Mar 16, the value is -2.35. This value is below the healthy minimum of 10. It has increased from -146.84 (Mar 15) to -2.35, marking an increase of 144.49.
- For PBT Margin (%), as of Mar 16, the value is -12.23. This value is below the healthy minimum of 10. It has increased from -156.99 (Mar 15) to -12.23, marking an increase of 144.76.
- For Net Profit Margin (%), as of Mar 16, the value is -8.16. This value is below the healthy minimum of 5. It has increased from -152.48 (Mar 15) to -8.16, marking an increase of 144.32.
- For NP After MI And SOA Margin (%), as of Mar 16, the value is -8.16. This value is below the healthy minimum of 8. It has increased from -152.48 (Mar 15) to -8.16, marking an increase of 144.32.
- For Return on Networth / Equity (%), as of Mar 16, the value is -0.36. This value is below the healthy minimum of 15. It has increased from -4.48 (Mar 15) to -0.36, marking an increase of 4.12.
- For Return on Capital Employeed (%), as of Mar 16, the value is -0.06. This value is below the healthy minimum of 10. It has increased from -2.56 (Mar 15) to -0.06, marking an increase of 2.50.
- For Return On Assets (%), as of Mar 16, the value is -0.21. This value is below the healthy minimum of 5. It has increased from -2.65 (Mar 15) to -0.21, marking an increase of 2.44.
- For Long Term Debt / Equity (X), as of Mar 16, the value is 0.63. This value is within the healthy range. It has increased from 0.62 (Mar 15) to 0.63, marking an increase of 0.01.
- For Total Debt / Equity (X), as of Mar 16, the value is 0.63. This value is within the healthy range. It has increased from 0.62 (Mar 15) to 0.63, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 16, the value is 0.02. It has increased from 0.01 (Mar 15) to 0.02, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 16, the value is 29.59. This value exceeds the healthy maximum of 3. It has increased from 15.97 (Mar 15) to 29.59, marking an increase of 13.62.
- For Quick Ratio (X), as of Mar 16, the value is 29.46. This value exceeds the healthy maximum of 2. It has increased from 15.89 (Mar 15) to 29.46, marking an increase of 13.57.
- For Interest Coverage Ratio (X), as of Mar 16, the value is 5.76. This value is within the healthy range. It has increased from -0.95 (Mar 15) to 5.76, marking an increase of 6.71.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 16, the value is 0.17. This value is below the healthy minimum of 3. It has increased from -14.03 (Mar 15) to 0.17, marking an increase of 14.20.
- For Enterprise Value (Cr.), as of Mar 16, the value is 10.00. It has decreased from 10.11 (Mar 15) to 10.00, marking a decrease of 0.11.
- For EV / Net Operating Revenue (X), as of Mar 16, the value is 17.63. This value exceeds the healthy maximum of 3. It has decreased from 26.84 (Mar 15) to 17.63, marking a decrease of 9.21.
- For EV / EBITDA (X), as of Mar 16, the value is 31.01. This value exceeds the healthy maximum of 15. It has increased from -277.52 (Mar 15) to 31.01, marking an increase of 308.53.
- For MarketCap / Net Operating Revenue (X), as of Mar 16, the value is 3.12. This value exceeds the healthy maximum of 3. It has decreased from 5.29 (Mar 15) to 3.12, marking a decrease of 2.17.
- For Price / BV (X), as of Mar 16, the value is 0.13. This value is below the healthy minimum of 1. It has decreased from 0.15 (Mar 15) to 0.13, marking a decrease of 0.02.
- For Price / Net Operating Revenue (X), as of Mar 16, the value is 3.12. This value exceeds the healthy maximum of 3. It has decreased from 5.30 (Mar 15) to 3.12, marking a decrease of 2.18.
- For EarningsYield, as of Mar 16, the value is -0.02. This value is below the healthy minimum of 5. It has increased from -0.28 (Mar 15) to -0.02, marking an increase of 0.26.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dolphin Medical Services Ltd:
- Net Profit Margin: -8.16%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -0.06% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -0.36% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.17
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 29.46
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 93.41)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.63
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -8.16%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | No.417, Sanali Heavens, Ameerpet, Hyderabad Telangana 500073 | dolphincomplianceofficer@gmail.com www.dolphinmedicalservices.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. G V Mohan Prasad | Managing Director & CEO |
| Dr. M Lakshmi Sudha | WholeTime Director & CFO |
| Mr. Nanapaneni Buddha Sagar | Director |
| Mr. Narendra Seena Karkera | Independent Director |
| Mr. Vinay Vishnuraj Nayak | Independent Director |
FAQ
What is the intrinsic value of Dolphin Medical Services Ltd?
Dolphin Medical Services Ltd's intrinsic value (as of 11 December 2025) is 0.25 which is 89.96% lower the current market price of 2.49, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 3.76 Cr. market cap, FY2025-2026 high/low of 3.30/1.98, reserves of ₹-5.02 Cr, and liabilities of 12.21 Cr.
What is the Market Cap of Dolphin Medical Services Ltd?
The Market Cap of Dolphin Medical Services Ltd is 3.76 Cr..
What is the current Stock Price of Dolphin Medical Services Ltd as on 11 December 2025?
The current stock price of Dolphin Medical Services Ltd as on 11 December 2025 is 2.49.
What is the High / Low of Dolphin Medical Services Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Dolphin Medical Services Ltd stocks is 3.30/1.98.
What is the Stock P/E of Dolphin Medical Services Ltd?
The Stock P/E of Dolphin Medical Services Ltd is .
What is the Book Value of Dolphin Medical Services Ltd?
The Book Value of Dolphin Medical Services Ltd is 6.68.
What is the Dividend Yield of Dolphin Medical Services Ltd?
The Dividend Yield of Dolphin Medical Services Ltd is 0.00 %.
What is the ROCE of Dolphin Medical Services Ltd?
The ROCE of Dolphin Medical Services Ltd is 0.18 %.
What is the ROE of Dolphin Medical Services Ltd?
The ROE of Dolphin Medical Services Ltd is 0.30 %.
What is the Face Value of Dolphin Medical Services Ltd?
The Face Value of Dolphin Medical Services Ltd is 10.0.